Shots:
BioVersys & Shionogi have entered into a global research & exclusive license option agreement to co-develop novel ansamycin compounds from BioVersys’ BV500 program into clinical candidates for treating NTM infections
Shionogi will gain access to BioVersys’ ansamycin chemistry platform & BV500 program, with an exclusive option to license selected molecules for clinical development &…
